Skip to content
value.today

Metagenomi Therapeutics, Inc.

MGX
$30 Mmarket cap on Oct 28, 2026
Compare
World rank
#23,010
Revenue
$25 M
For year ending December-2025
Net income
$-88 M
-348.6% margin
SEC filing
Employees
119
As of December 31, 2025
SEC filing

Metagenomi Therapeutics, Inc. in brief

Metagenomi Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Emeryville, California, USA. Its market value was $30 M on 28 October 2026, which makes it the 23,010th largest listed company in the world and the 4,038th largest in the USA on this site. In the year to December 2025 it had sales of $25 M and a net loss of $88 M. It employs about 119 people. Its shares trade under the symbol MGX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Metagenomi Therapeutics, Inc.

We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems. In late 2025, we made the decision to strategically reprioritize our pipeline and discovery efforts to focus our resources on driving forward our lead programs that utilize our most advanced, signature gene-editing capabilities with the highest probability of success while maintaining financial discipline to drive sustainable growth and long-term value. We increased our focus on high-value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways to accelerate programs with the potential to deliver therapeutic benefits of gene editing to patients.

From the company's annual report filed with the US SEC: read the report

Metagenomi Therapeutics, Inc. timeline

5 events, 2019–2026
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 💰
    Record revenue of $52 million
    FY2024, the highest of the 3 years on record.
  5. ✎
    Renamed Metagenomi, Inc.
    Formerly Metagenomi Technologies, LLC.
  6. 🔔
    Initial public offering as Metagenomi, Inc.
    Final prospectus filed with the SEC on 12 February 2024; shares registered for exchange trading on 5 February 2024.
  7. 2026
  8. ✎
    Renamed Metagenomi Therapeutics, Inc.
    Formerly Metagenomi, Inc..

Events of Metagenomi Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$12 M$25 M$37 M$50 M

World rank over time

▼ down 3,368 places since 2026
2026-08-01: #19668#19,66820262026-10-13: #22273#22,27320262026-10-28: #23036#23,0362026

Rank in USA: #3,763 (Aug 2026) · #3,934 (Oct 2026) · #4,041 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
1.2×
Price / book
0.2×
Free cash flow yield
-295.8%
Net margin
-348.6%
Operating margin
-380.8%
Return on equity
-55.4%
Liabilities / assets
28.3%
Revenue growth
-51.8%
R&D / revenue
374.6%
Revenue per employee
$212 K
Profit per employee
$-738 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue $45M, net income $-68M$45MFY23Fiscal year ending Dec 2024: revenue $52M, net income $-78M$52MFY24Fiscal year ending Dec 2025: revenue $25M, net income $-88M$25MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$25M-51.8%$-96M$-88M-348.6%
Dec 2024$52M+16.8%$-89M$-78M-149.3%
Dec 2023$45M—$-78M$-68M-152.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-89M$1M$-89M$-2.36—
Dec 2024$-109M$3M$-112M$-2.36—
Dec 2023$-91M$10M$-101M$-20.05—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $10M, net income $-23M$10MDec ’24Three months to Mar 2025: revenue $4M, net income $-25M$4MMar ’25Three months to Jun 2025: revenue $9M, net income $-20M$9MJun ’25Three months to Sep 2025: revenue $9M, net income $-20M$9MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-23M$4MDec ’25Three months to Mar 2026: revenue $1M, net income $-23M$1MMar ’26Three months to Jun 2026: revenue —, net income $-27M—Jun ’26Three months to Sep 2026: revenue $2M, net income $-21M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (-74.8% on a year earlier), net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Metagenomi Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$25 M
Operating income
$-96 M
Net income
$-88 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$221 M
Total liabilities
$63 M
Total equity
$159 M

As of December-2025

Top 44 institutional investors in Metagenomi Therapeutics, Inc.#

As of Sep 30, 2026
44 institutions held 6.0 M shares (about 15.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 12.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Metagenomi Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC1,077,7000 (0.00%)2.85%$1 MNov 13, 2026
2Renaissance Technologies LLC624,300-118,100 (-15.91%)1.65%$1 MNov 12, 2026
3Catalio Capital Management, LP528,9930 (0.00%)1.40%$1 MNov 16, 2026
4Two Sigma Investments, LP504,515-9,186 (-1.79%)1.33%$1 MNov 16, 2026
5Peapod Lane Capital LLC490,992-34,032 (-6.48%)1.30%$1 MOct 22, 2026
6Wells Fargo & Company/mn424,687+45,179 (+11.90%)1.12%$0 MNov 16, 2026
7Bridgeway Capital Management, LLC375,300-25,000 (-6.25%)0.99%$0 MNov 16, 2026
8Almitas Capital LLC282,308New0.75%$0 MNov 17, 2026
9Geode Capital Management, LLC275,088-13,577 (-4.70%)0.73%$0 MNov 6, 2026
10BlackRock, Inc.253,235-4,396 (-1.71%)0.67%$0 MNov 13, 2026
11Vanguard Fiduciary Trust Co171,2510 (0.00%)0.45%$0 MNov 13, 2026
12Man Group plc141,896+32,766 (+30.02%)0.38%$0 MNov 16, 2026
13State Street Corp119,8500 (0.00%)0.32%$0 MNov 12, 2026
14Resolute Advisors LLC89,9440 (0.00%)0.24%$0 MNov 16, 2026
15Millennium Management LLC75,402-38,623 (-33.87%)0.20%$0 MNov 16, 2026
16Northern Trust Corp68,9380 (0.00%)0.18%$0 MNov 16, 2026
17RBF Capital, LLC64,0210 (0.00%)0.17%$0 MNov 13, 2026
18BBR Partners, LLC53,4030 (0.00%)0.14%$0 MNov 16, 2026
19HRT Financial LP52,288New0.14%$0 MNov 13, 2026
20Citadel Advisors LLC49,266+31,415 (+175.98%)0.13%$0 MNov 16, 2026
21EFG International AG37,510New0.10%$0 MNov 16, 2026
22Fortitude Advisory Group L.L.C.37,290+100 (+0.27%)0.10%$0 MOct 15, 2026
23Empowered Funds, LLC37,200New0.10%$0 MNov 13, 2026
24XTX Topco Ltd32,499-23,208 (-41.66%)0.09%$0 MNov 16, 2026
25Two Sigma Securities, LLC28,109+12,936 (+85.26%)0.07%$0 MNov 16, 2026
Show all 44: investors 26 to 44
Institutional investors 26 to 44 in Metagenomi Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jane Street Group, LLC22,821-15,575 (-40.56%)0.06%$0 MNov 12, 2026
27UBS Group AG15,906+113 (+0.72%)0.04%$0 MNov 10, 2026
28Vanguard Global Advisers, LLC13,3920 (0.00%)0.04%$0 MNov 13, 2026
29Dimensional Fund Advisors LP12,7970 (0.00%)0.03%$0 MNov 4, 2026
30Tower Research Capital LLC (TRC)10,567+5,267 (+99.38%)0.03%$0 MNov 16, 2026
31Morgan Stanley6,366+1,064 (+20.07%)0.02%$0 MNov 13, 2026
32Meeder Asset Management Inc5,4960 (0.00%)0.01%$0 MNov 10, 2026
33US Bancorp \de\4,5000 (0.00%)0.01%$0 MNov 5, 2026
34Nuveen, LLC4,052New0.01%$0 MNov 10, 2026
35Osaic Holdings, Inc.1,8910 (0.00%)0.01%$0 MNov 12, 2026
36Jpmorgan Chase & Co1,5960 (0.00%)0.00%$0 MNov 12, 2026
37FMR LLC1,100+512 (+87.07%)0.00%$0 MNov 10, 2026
38Jones Financial Companies Lllp5000 (0.00%)0.00%$0 MNov 13, 2026
39Allworth Financial LP5000 (0.00%)0.00%$0 MNov 17, 2026
40Royal Bank Of Canada486New0.00%$0 MNov 16, 2026
41BNP Paribas Financial Markets21-186 (-89.86%)0.00%$0 MNov 12, 2026
42Caitong International Asset Management Co., Ltd10+2 (+25.00%)0.00%$0 MOct 29, 2026
43Barclays PLC3-164 (-98.20%)0.00%$0 MNov 6, 2026
44Optiver Holding B.V.20 (0.00%)0.00%$0 MNov 16, 2026

Mutual funds holding Metagenomi Therapeutics, Inc.#

12 funds hold shares worth $2 M (about 4.1% of the company). Since their previous reports 5 added shares and 2 sold, buying $0 M net.
Mutual funds holding Metagenomi Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.741,407$1 M2.0%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.315,460$0 M0.83%<0.01%−0.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC189,092$0 M0.50%<0.01%+25%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors95,479$0 M0.25%<0.01%+36%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC62,200$0 M0.16%0.05%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC47,211$0 M0.12%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC36,088$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC21,951$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.20,833$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC6,882$0 M0.02%<0.01%+32%Jun 30, 2026
🇺🇸 Spectrum FundMeeder Asset Management, Inc.5,496$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC2,600$0 M<0.01%<0.01%+4.0%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Metagenomi Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$23 K
2 purchases, 1 insider
Sold, 12 months
$33 K
13 sales, 4 insiders
Net, 12 months
-$10 K
open market only
Insiders on file
12
since
$13.0 M-$42 K$0Feb 2024: bought $13.0 M (2 trades), sold $0 (0 trades)Feb 24Sep 2024: bought $0 (0 trades), sold $18 K (1 trades)Dec 2024: bought $0 (0 trades), sold $3 K (1 trades)DecMar 2025: bought $0 (0 trades), sold $5 K (2 trades)Jun 2025: bought $0 (0 trades), sold $42 K (5 trades)JunSep 2025: bought $0 (0 trades), sold $11 K (4 trades)Dec 2025: bought $0 (0 trades), sold $13 K (4 trades)DecMar 2026: bought $0 (0 trades), sold $6 K (3 trades)Jun 2026: bought $0 (0 trades), sold $9 K (3 trades)JunSep 2026: bought $23 K (2 trades), sold $5 K (3 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Metagenomi Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Laurence ReidDirectorBuy+19,883$1.170$23 K19,883Form 4
filed Laurence ReidDirectorBuy+117$1.180$13820,000Form 4
filed Pamela WapnickChief Financial OfficerSell-1,911$1.160$2 K206,580Form 4
filed Jian IrishSee Remarks, DirectorSell-2,140$1.160$2 K375,393Form 4
filed Matthew WeinSee RemarksSell-358$1.160$415126,133Form 4
filed Pamela WapnickChief Financial OfficerSell-2,884$1.300$4 K208,491Form 4
filed Matthew WeinSee RemarksSell-558$1.300$725126,491Form 4
filed Jian IrishSee Remarks, DirectorSell-3,737$1.300$5 K377,533Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Metagenomi Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.3 M
3.5% of shares · 11.13 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.747-for-1 split

Trading halts

  • 2025-10-16 15:32 UTC, code LUDP, resumed 15:42 UTC
  • 2024-12-10 14:40 UTC, code LUDP, resumed 14:45 UTC
  • 2024-12-10 14:30 UTC, code LUDP, resumed 14:35 UTC

Fails to deliver

  • : 8,531 shares at $0.80
  • : 1,997 shares at $1.02
  • : 3 shares at $1.12
  • : 5,732 shares at $1.13
  • : 2,024 shares at $1.15

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Metagenomi Therapeutics, Inc. scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.2×Price to book 0.2× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.2×Price to sales 1.2× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • ✗Revenue grew in the newest year-51.8%Revenue down 51.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.36 vs -2.36Diluted EPS -2.36 in fiscal 2025 against -2.36 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$88 MNet income -$88 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-380.8%-380.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-44.7%-44.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities7.2×Current ratio 7.22 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.22Z-score -2.22 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year12.8%Diluted shares up 12.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Metagenomi Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Metagenomi Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-380.8%-60.5%
Net margin-348.6%-68.9%
Return on equity-44.7%-61.0%
Revenue growth-51.8%15.8%
Free cash flow margin-354.9%-61.5%

1of 7on the Piotroski tests of financial strength

  • Revenue fell 51.8% against the year before.
  • Net loss of $88 million, the 3th loss-making year in a row.
  • Free cash flow was negative: -$89 million.
  • The share count rose 12.8% in the year.

Metagenomi Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Metagenomi Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Revenue255245
Research and development9410994
General and administrative273229
Operating expenses121141123
Operating income−96−89−78
Interest and finance income9.51515
Other non-operating income (expense)8.15.318
Income before tax−88−84−60
Income tax−0.1−5.58.0
Net income including minority interests−88−78−68
Net income attributable to shareholders−88−78−68
Earnings per share, basic-2.36-2.36-20.05
Earnings per share, diluted-2.36-2.36-20.05
Shares, weighted average (basic)37333.4
Shares, weighted average (diluted)37333.4
Balance sheet
Cash and cash equivalents4227141
Short-term investments119221131
Receivables0.31.12.5
Other current assets4.48.44.6
Current assets166258278
Property, plant and equipment121822
Right-of-use (leased) assets354044
Long-term investments2.23.411
Total assets221325365
Accounts payable1.50.51.8
Current liabilities233769
Lease liabilities (non-current)354045
Total liabilities6390150
Retained earnings−311−223−145
Shareholders' equity159235−136
Total liabilities and equity221325365
Shares outstanding38373.4
Cash-flow statement
Share-based compensation12166.9
Cash from operating activities−89−109−91
Capital expenditure−0.6−3.1−9.8
Cash from investing activities104−8846
Cash from financing activities−0.4841.0
Change in cash14−113−45
Report10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Metagenomi Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · Agreement ended 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 13

Metagenomi Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreementAgreement ended8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Agreement endedResults announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Metagenomi Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$96 MNo. 5$50 to $250 million25equitySEC
Jan 2022$175 MNo. 4$50 to $250 million29equitySEC
Mar 2021$10 MNo. 3$10 to $50 million2equitySEC
Nov 2020$38 MNo. 2$10 to $50 million11equitySEC
Aug 2019$26 MNo. 1$10 to $50 million16equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Metagenomi Therapeutics, Inc.#

8 labor condition applications certified in fiscal 2026 for 8 positions, at a median wage of $130 K a year.

Certified, FY2026
8
#919 among companies on value.today
Worker positions
8
Median wage offered
$130 K
a year, full-time
Applications filed
8
Metagenomi Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Scientist IIBioinformatics Scientists3$135 K
Research Associate IIMolecular and Cellular Biologists2$90 K
Scientist IMolecular and Cellular Biologists2$123 K
Senior ScientistMolecular and Cellular Biologists1$145 K

Where: Emeryville, CA 8

Metagenomi Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202688$130 K8
FY20251010$107 K10
FY202444$118 K4
FY202399$96 K10
FY20221111$70 K12
FY202111$260 K2
FY202022$175 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Metagenomi.co

How Metagenomi Therapeutics, Inc. compares in Biotechnology

  • Market cap$30 M · higher than 22% of 726
  • Revenue$25 M · higher than 52% of 647
  • Net margin-348.6% · higher than 17% of 408
  • Revenue growth-51.8% · higher than 17% of 438
  • Price / sales1.2× · lower than 91% of 339
  • Price / book0.2× · lower than 99% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Metagenomi Therapeutics, Inc.🇺🇸$30 M—-348.6%-51.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Metagenomi Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Metagenomi Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Metagenomi Therapeutics, Inc.? Suggest a correction